D.A. Davidson & Co’s CRISPR Therapeutics CRSP Stock Holding History

D.A. Davidson & Co’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$301K	Buy	6,324 +353	+6%	+$18.6K	﹤0.01%	1350
2025 Q4	$313K	Buy	5,971 +592	+11%	+$35.5K	﹤0.01%	1300
2025 Q3	$349K	Buy	+5,379	New	+$309K	﹤0.01%	1258
2021 Q4	–	Sell	-2,942	Closed	-$329K	–	1270
2021 Q3	$329K	Buy	2,942 +356	+14%	+$44.7K	﹤0.01%	976
2021 Q2	$419K	Hold	2,586	–	–	﹤0.01%	881
2021 Q1	$315K	Buy	+2,586	New	+$390K	﹤0.01%	945
2018 Q4	–	Sell	-7,876	Closed	-$349K	–	1107
2018 Q3	$349K	Sell	7,876 -7,375	-48%	-$386K	0.01%	850
2018 Q2	$896K	Sell	15,251 -1	-0%	-$57	0.02%	533
2018 Q1	$697K	Sell	15,252 -500	-3%	-$20.6K	0.01%	582
2017 Q4	$370K	Buy	+15,752	New	+$299K	0.01%	761

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSK plc London $599M AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

D.A. Davidson & Co's CRSP Position: Q1 2026 in Review

D.A. Davidson & Co increased its CRISPR Therapeutics (CRSP) stake by 5.9% in Q1 2026, buying an estimated $18.6K and bringing the position to 6,324 shares worth $301K. The position accounts for ﹤0.01% of the portfolio, ranked #1350.

D.A. Davidson & Co first reported a position in CRSP in Q4 2017 and has held it in 10 quarters since. The position peaked at $896K in Q2 2018. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

D.A. Davidson & Co held 6,324 shares of CRISPR Therapeutics worth $301K as of Q1 2026.
D.A. Davidson & Co bought 353 CRISPR Therapeutics shares in Q1 2026, an estimated $18.6K.
CRISPR Therapeutics made up ﹤0.01% of D.A. Davidson & Co's portfolio in Q1 2026, its #1350 holding.
D.A. Davidson & Co first reported a position in CRISPR Therapeutics in Q4 2017 and has held it in 10 quarters since.
D.A. Davidson & Co's CRISPR Therapeutics position peaked at $896K in Q2 2018.
488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on D.A. Davidson & Co's 13F filing for Q1 2026, filed 5 May 2026.